Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Survey reveals need for nutrition education among African Americans for disease prevention, management

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.African Americans are 1.8 times more likely to develop Type 2 diabetes and 1.4 times more likely to be obese than are non-Hispanic whites, according to federal health agencies. Obesity is a leading risk factor for development of diabetes, a condition that results when the body cannot properly use insulin to transfer sugar from the blood to muscle and fat cells that use glucose for energy.

6 Aug 2010

Australia has highest rates of type 1 diabetes among children

Australia ranks the highest among 10 OECD countries when it comes to rate of type 1 diabetes among children, according to the Australian Institute of Health and Welfare (AIHW). The OECD or consists of 32 countries.

5 Aug 2010

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Citing research that demonstrates the cost savings and health benefits of providing Diabetes Self-Management Training (DSMT) to patients with pre-diabetes, the American Association of Diabetes Educators today called on private insurers and Medicare to include education as a covered benefit for this population.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Roche inaugurates National Infusion Site Awareness Week to promote diabetis management

Roche Diabetes Care, makers of the ACCU-CHEK portfolio of diabetes management products and services, is pleased to announce the inaugural National Infusion Site Awareness Week, Aug. 30-Sept. 5. Roche made the announcement during the 37th annual American Association of Diabetes Educators (AADE) conference to highlight the important role that certified diabetes educators and other health care professionals play in promoting better site management for the 400,000 people in the United States with Type 1 diabetes who use an insulin pump.

5 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.

3 Aug 2010

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

3 Aug 2010

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

WellDoc DiabetesManager System receives FDA clearance

WellDoc, a healthcare company that develops technology solutions to improve chronic disease management outcomes and reduce healthcare costs, today announced that it has received United States Food and Drug Administration 510(k) clearance to market the WellDoc DiabetesManager System to healthcare providers and their adult patients with type 2 diabetes.

2 Aug 2010

MannKind second-quarter total operating expenses decrease to $16.0 million

MannKind Corporation today reported financial results for the second quarter ended June 30, 2010.

2 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Resveratrol suppresses inflammation in humans: Research

Resveratrol, a popular plant extract shown to prolong life in yeast and lower animals due to its anti-inflammatory and antioxidant properties, appears also to suppress inflammation in humans, based on results from the first prospective human trial of the extract conducted by University at Buffalo endocrinologists.

31 Jul 2010

Resveratrol suppresses inflammation and free radicals: Study

30 Jul 2010

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

30 Jul 2010

Nutrisystem second-quarter revenues increase 8% to $141.6 million

Nutrisystem, Inc., a leading provider of weight management products and services, today reported financial results for the second quarter of 2010.

30 Jul 2010

Study explores benefits, risks of aggressive blood sugar control in hemodialysis patients

Aggressive blood sugar control does not improve survival in diabetic patients with kidney failure, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that physicians should individualize blood sugar targets for these patients and not rely on recommendations based on studies in the general population.

30 Jul 2010

Study on link between SNP and concentrations of serum creatinine

Scientists at deCODE genetics and colleagues at Radboud University in the Netherlands today describe how the impact of a single letter variation in the sequence of the human genome conferring risk of kidney disease varies with age and with the onset of other diseases. The study provides independent confirmation of the association made in an earlier study between a version of the the SNP, located on chromosome 16p12, and risk of chronic kidney disease. It also confirmed the link between the SNP and concentrations of serum creatinine, a key indicator of kidney function.

30 Jul 2010